An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT07426757
Trial Phases:	Phase I	Protocol IDs:	C6331001 (primary) NCI-2026-04029 KAT2i
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Pfizer Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT07426757

Summary

This is an open-label, dose escalation and dose expansion study evaluating the safety,
tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of
PF-07994525 in participants with R/R MM.

The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525
dose escalation to assess the safety, tolerability, and preliminary antitumor activity in
participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in
additional participants with R/R MM to further assess safety, PK, PD, and preliminary
anti-tumor activity.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.